Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 794 GBX -0.83% Market Closed
Market Cap: 4B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Hikma Pharmaceuticals PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hikma Pharmaceuticals PLC
Additional Paid In Capital Peer Comparison

Comparables:
GSK
AZN
VRNA
INDV
DPH

Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Additional Paid In Capital
$282m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
GlaxoSmithKline PLC
LSE:GSK
Additional Paid In Capital
ÂŁ3.5B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Additional Paid In Capital
$35.2B
CAGR 3-Years
64%
CAGR 5-Years
35%
CAGR 10-Years
24%
Verona Pharma PLC
NASDAQ:VRNA
Additional Paid In Capital
$621.6m
CAGR 3-Years
18%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Additional Paid In Capital
$11m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Additional Paid In Capital
ÂŁ596m
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
17%

See Also

What is Hikma Pharmaceuticals PLC's Additional Paid In Capital?
Additional Paid In Capital
282m USD

Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Additional Paid In Capital amounts to 282m USD.

What is Hikma Pharmaceuticals PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
0%

Over the last year, the Additional Paid In Capital growth was 0%.

Back to Top